Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $80.91 in the prior trading day, Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) closed at $82.13, up 1.51%. In other words, the price has increased by $1.51 from its previous closing price. On the day, 2.01 million shares were traded. BMRN stock price reached its highest trading level at $83.84 during the session, while it also had its lowest trading level at $81.44.
Ratios:
Our goal is to gain a better understanding of BMRN by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 85.73. For the most recent quarter (mrq), Quick Ratio is recorded 1.70 and its Current Ratio is at 2.74. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on November 15, 2023, initiated with a Overweight rating and assigned the stock a target price of $100.
On October 23, 2023, Bernstein Upgraded its rating to Mkt Perform which previously was Underperform but kept the price unchanged to $82.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 12 ’24 when BIENAIME JEAN JACQUES sold 20,000 shares for $91.26 per share. The transaction valued at 1,825,200 led to the insider holds 474,994 shares of the business.
BIENAIME JEAN JACQUES sold 20,000 shares of BMRN for $1,819,800 on Apr 11 ’24. The Director now owns 474,994 shares after completing the transaction at $90.99 per share. On Apr 10 ’24, another insider, Burkhart Erin, who serves as the GVP, Chief Accounting Officer of the company, sold 2,286 shares for $90.00 each. As a result, the insider received 205,740 and left with 16,156 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BMRN now has a Market Capitalization of 15586383872 and an Enterprise Value of 15644784640. As of this moment, Biomarin’s Price-to-Earnings (P/E) ratio for their current fiscal year is 76.86, and their Forward P/E ratio for the next fiscal year is 32.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.79. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.30 while its Price-to-Book (P/B) ratio in mrq is 3.07. Its current Enterprise Value per Revenue stands at 6.33 whereas that against EBITDA is 53.31.
Stock Price History:
The Beta on a monthly basis for BMRN is 0.34, which has changed by -0.12460029 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, BMRN has reached a high of $99.56, while it has fallen to a 52-week low of $76.02. The 50-Day Moving Average of the stock is -6.24%, while the 200-Day Moving Average is calculated to be -7.78%.
Shares Statistics:
The stock has traded on average 1.53M shares per day over the past 3-months and 2154260 shares per day over the last 10 days, according to various share statistics. A total of 188.60M shares are outstanding, with a floating share count of 185.93M. Insiders hold about 2.03% of the company’s shares, while institutions hold 98.83% stake in the company. Shares short for BMRN as of 1713139200 were 3688638 with a Short Ratio of 2.41, compared to 1710460800 on 2964290. Therefore, it implies a Short% of Shares Outstanding of 3688638 and a Short% of Float of 1.96.
Earnings Estimates
The market rating for Biomarin Pharmaceutical Inc. (BMRN) is a result of the insights provided by 18.0 analysts actively involved in the assessment.On average, analysts expect EPS of $0.35 for the current quarter, with a high estimate of $0.45 and a low estimate of $0.17, while EPS last year was $0.29. The consensus estimate for the next quarter is $0.47, with high estimates of $0.6 and low estimates of $0.27.
Analysts are recommending an EPS of between $2.12 and $0.42 for the fiscal current year, implying an average EPS of $1.72. EPS for the following year is $2.63, with 21.0 analysts recommending between $4.04 and $1.29.
Revenue Estimates
For the next quarter, 23 analysts are estimating revenue of $692.02M. There is a high estimate of $728.22M for the next quarter, whereas the lowest estimate is $672.54M.
A total of 28 analysts have provided revenue estimates for BMRN’s current fiscal year. The highest revenue estimate was $2.84B, while the lowest revenue estimate was $2.61B, resulting in an average revenue estimate of $2.74B. In the same quarter a year ago, actual revenue was $2.42BBased on 27 analysts’ estimates, the company’s revenue will be $3.1B in the next fiscal year. The high estimate is $3.32B and the low estimate is $2.82B.
